Vascular phenotypes in primary non-small cell lung carcinomas and matched brain metastases

BACKGROUND: Anti-angiogenic therapy with bevacizumab (an anti-vascular endothelial growth factor (VEGF) antibody) predominantly targets immature blood vessels. Bevacizumab has shown a survival benefit in non-small cell lung carcinoma (NSCLC) and has recently been demonstrated to be safe in patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Jubb, A M, Cesario, A, Ferguson, M, Congedo, M T, Gatter, K C, Lococo, F, Mulè, A, Pezzella, F
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2011
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3111192/
https://www.ncbi.nlm.nih.gov/pubmed/21540863
http://dx.doi.org/10.1038/bjc.2011.147

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3111192/
https://www.ncbi.nlm.nih.gov/pubmed/21540863
http://dx.doi.org/10.1038/bjc.2011.147

Ejemplares similares